CNS Pharmaceuticals, Inc. - Common Stock (CNSP)

Glioblastoma multiforme is an aggressive type of cancer that primarily affects the brain. A new study has found that this cancer has an internal clock which is synced every day to capitalize on the circadian rhythm of the patient. This feature allows tumors to grow as the patient’s body releases hormones.

CNS Pharmaceuticals (NASDAQCNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30 a.m. to 1 p.m. ET. The event will feature presentations by the company’s leadership team, including CEO John Climaco, Chief Medical Officer Dr. Sandra Silberman, and VP of Clinical Operations Zena Muzyczenko, alongside key opinion leaders Dr. Michael Weller, Dr. Samuel Goldlust, and Dr. Erin Dunbar. Discussions will focus on glioblastoma multiforme (“GBM”), updates on the clinical development of Berubicin, and regulatory strategies for the company’s second asset, TPI 287. A live video webcast and replay will be available on the company’s website.

Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders

Central nervous system and brain cancers accounted for 248,500 deaths globally in 2022. In America, roughly 90,000 brain tumors are diagnosed annually, with data from the American Cancer Society showing that over 25,000 of these tumors are cancerous. It is projected that there’ll be an estimated 25,400 new cases of central nervous system and brain cancers in 2024.

CNS Pharmaceuticals (NASDAQCNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent glioblastoma multiforme (“GBM”). Presented at the 29th Annual Meeting of the Society for Neuro-Oncology, the data show balanced patient demographics and safety profiles between the study arms, with Berubicin showing comparable adverse event rates and promising potential to improve overall survival (“OS”), the trial’s primary endpoint. With enrollment completed at 252 patients, CNS expects to report primary analysis data in early 2025. Berubicin holds FDA Fast Track and Orphan Drug Designations, underscoring its significance in advancing GBM treatment options.

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025

Researchers have developed a chip that may revolutionize how brain cancer is treated. This revolutionary device is made of graphene, a material made of pure carbon that’s over a hundred times stronger than steel.

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller

Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals (NASDAQCNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology. The presentation, led by Chief Medical Officer Dr. Sandra Silberman, will provide updates on the randomized, controlled CNS-201 trial comparing Berubicin to Lomustine after first-line GBM therapy. The session will take place on Nov. 22, 2024, at the George R. Brown Convention Center in Houston, TX, during the Poster and Networking Session.

HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQCNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX.

CNS Pharmaceuticals (NASDAQCNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast Track and Orphan Drug Designations from the FDA. The company also licensed TPI 287, a late-stage candidate for brain malignancies, with plans for FDA engagement on future studies. CNS ended the quarter with $7.0 million in cash and additional funding, ensuring operations through Q2 2025.

Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust

Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET

Webcast presentation on Wednesday, September 25th at 1:55 PM CEST

CNS Pharmaceuticals (NASDAQCNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, a renowned neuro-oncologist and National Coordinating Investigator for CNS’s study on Berubicin. During the event, Professor Weller discussed the urgent need for effective treatments in glioblastoma multiforme (“GBM”), exploring how Berubicin could serve as a promising therapy within the current limited treatment landscape for this aggressive brain cancer.

CNS Pharmaceuticals (NASDAQCNSP) announced that it received an exception from the Nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This extension allows CNS additional time to regain compliance and maintain its listing status.

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQCNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2).

These five companies, all trading under $0.10, present speculative opportunities for investors looking to find undervalued businesses with tremendous upside potential. As October unfolds, these stocks may witness significant market movements, offering attractive entry points for those willing to take calculated risks.

CNS Pharmaceuticals (NASDAQCNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities purchase agreements with institutional investors to raise approximately $3 million. The funding will come from the sale of 17,647,060 shares of common stock, priced at $0.17 per share, in a registered direct offering. The proceeds will be used for general corporate purposes and working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction, which is expected to close today, Oct. 24, 2024, pending customary conditions.

HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQCNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock (or common stock equivalents in lieu thereof) pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share.

CNS Pharmaceuticals (NASDAQCNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company announced Thursday morning that it participated in a Virtual Investor KOL Connect segment. Members of the company’s management team and Dr. Samuel Goldlust, who previously served as an investigator in the company’s global potentially pivotal study of Berubicin, joined the segment to provide a corporate update, discuss the unmet need in glioblastoma multiforme (“GBM”), and highlight the opportunity for the company.

In August 2015, former president Jimmy Carter revealed at a conference held at the Carter Center that cancer had spread to his brain . Carter, then aged 91, discussed how his initial diagnosis of melanoma had led to the disease’s spread. If he had been diagnosed with the illness just a few years prior, he would have had about six months to live. Instead, the former president celebrated his 100th birthday on Oct. 1, 2024.

CNS Pharmaceuticals (NASDAQCNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A recently conducted review has determined that there’s no correlation between the use of mobile phones and a heightened risk of acoustic neuromas, meningiomas and gliomas. The review also found no correlation between mobile phone use and leukemia or salivary and pituitary cancers.